The document summarizes an analytical validation of the Oncomine Comprehensive Assay v3 (OCAv3) targeted next-generation sequencing panel performed in a CLIA-certified laboratory. The validation assessed analytical sensitivity, specificity, accuracy, and precision using formalin-fixed paraffin-embedded tumor samples and cell lines. Results showed the assay met performance thresholds of 90% or higher for detecting single nucleotide variants, insertions/deletions, copy number variants, and gene fusions across a wide range of variants. Over 2,500 clinical samples were subsequently sequenced with the assay maintaining a 95% success rate and average turnaround time of 10 days.